Tumor-to-Liver Ratio of Ga-68-DOTATOC PET/CT as a Prognostic Parameter in Metastatic, Well-Differentiated Gastroenteropancreatic-Neuroendocrine Tumor Patients Who Received Lanreotide Therapy

#2777

Introduction: Lanreotide is a long-acting somatostatin analogue with proven antitumor effect against metastatic, well-differentiated gastroenteropancreatic-neuroendocrine tumors (GEP-NETs). Ga-68-DOTATOC PET/CT is a sensitive imaging technique for NETs by targeting somatostatin receptors.

Aim(s): We investigated the prognostic value of Ga-68-DOTATOC PET/CT in patients with metastatic, well-differentiated GEP-NETs treated by lanreotide.

Materials and methods: Thirty-one patients with metastatic, well-differentiated GEP-NETs were retrospectively enrolled (mean age; 55.1 ± 15.5 yr, M:F = 12:19). As clinicopathologic parameters, ECOG performance status, primary tumor site, WHO grade, presence of carcinoid symptom, prior surgery, prior chemotherapy, and hepatic tumor volume assessed by CT/MRI were identified. As Ga-68-DOTATOC PET/CT parameters, Krenning score, tumor-to-liver ratio (TLR), maximum standardized uptake value (SUVmax), whole tumor volume (WTV) and total receptor expression (WTV multiplied by SUVmean) were assessed. The primary endpoint was progression-free survival (PFS).

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Kim Y, Yoo C, Ryoo B, Ryu J,

Keywords: neuroendocrine tumor, lanreotide, somatostatin receptor, DOTATOC, positron emission tomography, prognosis,